Why the study?
Do antagonists of the renin-angiotensin system mitigate radiation nephropathy and other normal tissue radiation injuries?
Do antagonists of the renin-angiotensin system mitigate radiation nephropathy and other normal tissue radiation injuries?
Renin-angiotensin system antagonists, such as ACE inhibitors and ARBs, represent a promising therapeutic strategy for mitigating and treating radiation nephropathy.
Supports RAS antagonist evaluation for radiation injuries; leaves open confirmation in prospective trials.
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: